Ascendis Pharma Files 6-K for SEC Reporting
Ticker: ASND · Form: 6-K · Filed: Mar 28, 2025 · CIK: 1612042
| Field | Detail |
|---|---|
| Company | Ascendis Pharma A/S (ASND) |
| Form Type | 6-K |
| Filed Date | Mar 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, reporting
TL;DR
Ascendis Pharma filed a routine 6-K, nothing major to see here.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on March 28, 2025, to report information as a foreign private issuer. The filing is incorporated by reference into several Form S-8 registration statements, which are used for employee stock plans.
Why It Matters
This filing indicates Ascendis Pharma is meeting its ongoing reporting obligations as a foreign private issuer with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This is a standard SEC filing for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 001-36815 (company) — SEC File Number
- 333-203040 (company) — Form S-8 Registration Number
- 333-210810 (company) — Form S-8 Registration Number
- 333-211512 (company) — Form S-8 Registration Number
- 333-213412 (company) — Form S-8 Registration Number
- 333-214843 (company) — Form S-8 Registration Number
- 333-216883 (company) — Form S-8 Registration Number
FAQ
What type of filing is Ascendis Pharma A/S submitting?
Ascendis Pharma A/S is submitting a Form 6-K report.
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of a foreign private issuer pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
When was this Form 6-K filed?
This Form 6-K was filed on March 28, 2025.
What is Ascendis Pharma A/S's principal executive office address?
Ascendis Pharma A/S's principal executive office is located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
What other SEC filings are referenced in this report?
This report is incorporated by reference into several registration statements on Form S-8, including Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, and 333-216883.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 28, 2025 regarding Ascendis Pharma A/S (ASND).